Cresset Asset Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Cresset Asset Management’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-918	Closed	-$38K	–	922
2022 Q3	$38K	Sell	918 -82	-8%	-$3.75K	﹤0.01%	863
2022 Q2	$42K	Sell	1,000 -500	-33%	-$23.2K	﹤0.01%	913
2022 Q1	$102K	Buy	1,500 +1,000	+200%	+$83.2K	﹤0.01%	938
2021 Q4	$61K	Hold	500	–	–	﹤0.01%	1101
2021 Q3	$70K	Hold	500	–	–	﹤0.01%	1088
2021 Q2	$137K	Buy	+500	New	+$126K	﹤0.01%	977

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cresset Asset Management's EVLO Position: Q4 2022 in Review

Cresset Asset Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2022, closing a stake of 918 shares — an estimated $38K sold.

Cresset Asset Management first reported a position in EVLO in Q2 2021 and held it in 6 quarters. The position peaked at $137K in Q2 2021. 44 funds tracked by Wall St. Rank hold EVLO as of Q4 2022.

Cresset Asset Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Cresset Asset Management sold 918 Evelo Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $38K.
Cresset Asset Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Cresset Asset Management's Evelo Biosciences, Inc. Common Stock position peaked at $137K in Q2 2021.
44 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2022.

Based on Cresset Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.